469 related articles for article (PubMed ID: 27355337)
1. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
3. Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?
Bhattacharya P; Abderrahman B; Jordan VC
Expert Rev Anticancer Ther; 2017 Apr; 17(4):297-310. PubMed ID: 28281842
[TBL] [Abstract][Full Text] [Related]
4. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H
Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273
[TBL] [Abstract][Full Text] [Related]
5. [Strategy of drug development for hormone-dependent tumor].
Kudoh M
Gan To Kagaku Ryoho; 1996 May; 23(6):668-72. PubMed ID: 8645015
[TBL] [Abstract][Full Text] [Related]
6. The future of antihormone therapy: innovations based on an established principle.
Parczyk K; Schneider MR
J Cancer Res Clin Oncol; 1996; 122(7):383-96. PubMed ID: 8690748
[TBL] [Abstract][Full Text] [Related]
7. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
10. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.
Jordan VC
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25269699
[TBL] [Abstract][Full Text] [Related]
11. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
12. Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer.
Jiang Q; Zheng S; Wang G
Future Med Chem; 2013 Jun; 5(9):1023-35. PubMed ID: 23734685
[TBL] [Abstract][Full Text] [Related]
13. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
14. The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.
Fan P; Maximov PY; Curpan RF; Abderrahman B; Jordan VC
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):245-63. PubMed ID: 26052034
[TBL] [Abstract][Full Text] [Related]
15. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
16. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
Sengupta S; Jordan VC
Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
[TBL] [Abstract][Full Text] [Related]
18. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
[TBL] [Abstract][Full Text] [Related]
19. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
20. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
Pienta KJ;
Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
